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Introduction: Flares in patients with rheumatoid arthritis are suggested to sometimes spontaneously resolve.
Targeted therapy could then entail possible overtreatment. We aimed to determine the flare prevalence in patients
who are treated-to-target and to evaluate associations between flares and patient-reported outcomes and
radiographic progression.
Methods: In the BeSt study, 508 patients were treated-to-target for 10 years. After initial treatment adjustments to
achieve disease activity score ≤2.4, a flare was defined from the second year of follow-up onwards, according to
three definitions. The first definition is a disease activity score >2.4 with an increase of ≥0.6 regardless of the
previous disease activity score. The other definitions will be described in the manuscript.
Results: The flare prevalence was 4–11 % per visit; 67 % of the patients experienced ≥1 flare during 9 years of
treatment (median 0 per patient per year). During a flare, functional ability decreased with a mean difference of
0.25 in health assessment questionnaire (p < 0.001), and the odds ratios (95 % confidence intervals) for an increase
in patients’ assessment of disease activity, pain and morning stiffness of ≥20 mm on a visual analogue scale were
8.5 (7.3–9.8), 8.4 (7.2–9.7) and 5.6 (4.8–6.6), respectively, compared to the absence of a flare. The odds ratio for
radiographic progression was 1.7 (1.1–2.8) in a year with a flare compared to a year without a flare. The more flares
a patient experienced, the higher the health assessment questionnaire at year 10 (p < 0.001) and the more
radiographic progression from baseline to year 10 (p = 0.005).
Conclusion: Flares were associated with concurrent increase in patient’s assessment of disease activity, pain and
morning stiffness, functional deterioration and development of radiographic progression with a dose–response-
effect, both during the flare and long term. This suggests that intensifying treatment during a flare outweighs the
risk of possible overtreatment.
Trial registration: Dutch trial registry NTR262 (7 September 2005) and NTR265 (8 September 2005).Introduction
Despite current effective treatment of patients with
rheumatoid arthritis (RA), episodes of increased disease
activity still may occur [1, 2]. These episodes are gener-
ally referred to as ‘flares’. What constitutes a flare can be
a matter for debate. This partly hinges on the fact that
patients may experience a flare which, for logistic or* Correspondence: i.m.markusse@lumc.nl
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this article, unless otherwise stated.other reasons, cannot be registered as an increase in dis-
ease activity. Therefore the notion of a flare is challen-
ging [1–3]. It is generally understood, though, that flares
are associated with concurrent deterioration of patient-
reported outcomes. When the increase in disease activity
is registered, flares are often managed with treatment in-
tensification [3–6]. Following a treat-to-target strategy,
treatment should be adjusted when a predefined target
has not been achieved or maintained. It has proven to
be effective in trials [7, 8], and is under the concept of
‘tight control’ also adopted in the recommendations forticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
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eously resolve. In that case, targeted therapy entails the
possibility of overtreatment.
In the BeSt study, treatment was targeted at low dis-
ease activity (disease activity score (DAS) ≤2.4, using the
original DAS based on a 53/44 joints assessment), with
3-monthly DAS measurements over 10 years. In this
post-hoc analysis, we aimed to examine the prevalence
of flares defined by increases in disease activity, and to
determine the short-term and long-term effects of these




The multicenter, clinical trial BeSt (Dutch acronym for
treatment strategies) with 10-year follow-up enrolled
508 patients with recent-onset, active RA according to
the 1987 criteria [11]. Treatment adjustments were made
based on 3-monthly DAS measurements, targeted at low
disease activity (DAS ≤2.4). If DAS was >2.4, medication
was intensified. As long as the DAS was ≤2.4 (from at
least 6 months), combination therapy was tapered to
monotherapy (usually methotrexate monotherapy), and
then monotherapy was tapered to a maintenance dose.
When DAS was <1.6 for at least 6 months during a
maintenance dose, medication was discontinued, but as
soon as DAS increased to >1.6, the last effective medication
was restarted and, when DAS increased to >2.4, treatment
was further intensified. The study protocol was approved
by the medical ethics committees of all participating centers
(listed in the Acknowledgements) and all patients gave
written informed consent. More details on the BeSt
study protocol were previously published [12].
End points
During year 1, initial treatment adjustments were made
to achieve the target of low disease activity in most pa-
tients. From the second year on, the presence or absence
of a flare was defined per visit. No unambiguous definition
of a flare is yet established but, recently, a flare definition
based on the 28-joint DAS (DAS28) was validated [5].
From this definition, we derived three definitions of flare
based on the 44-joint DAS. Our definitions are partially
overlapping, but were always tested separately. ‘Flare A’ was
defined as DAS >2.4, with an increase in DAS of at least 0.6
from a previous DAS of any value. A ‘minor flare B’ was de-
fined as DAS >2.4, from a previous DAS ≤2.4 with an in-
crease in DAS <0.6, and a ‘major flare B’ as DAS >2.4 from
a previous DAS ≤2.4 with an increase in DAS of ≥0.6.
The cut-off for DAS of 2.4 was chosen based on the
target of the BeSt study. The cut-off for the difference in
DAS of 0.6 was based on the European League Against
Rheumatism (EULAR) criteria, where a decrease of >0.6in DAS is stated as a (clinically relevant) response [13].
Consequently, we classified a ≥0.6 increase in DAS as a
(clinically relevant) deterioration. It is unknown whether
we should take into account the absolute value of the
previous DAS (thus, not only the change in DAS) when
defining a flare. Therefore, flare A and major flare B
were distinguished.
Functional ability was measured 3-monthly using the
health assessment questionnaire (HAQ; range 0–3) [14].
An improvement of 0.22 in HAQ is considered to repre-
sent a clinically relevant improvement [15]. Hence, an
increase of 0.22 was considered to be a clinically relevant
deterioration. At every visit, patients filled in several vis-
ual analogue scales (VAS; range 0–100 mm), assessing
general health (VASgh), disease activity (VASda), pain
(VASpain) and morning stiffness (VASms). As VASgh is
part of the DAS calculation [16], this score was not used
for further analysis. A clinically relevant cut-off for an
increase in VAS of at least 20 mm difference, as pro-
posed by Khan et al. [17], was used to test whether pa-
tients during a flare report higher VAS scores than in
situations without a flare.
Joint damage progression was assessed on radiographs
of hands and feet using the Sharp/ van der Heijde score
(SHS; range 0–448) [18]. Radiographs were obtained
yearly and were scored in one session, in random order,
by two blinded readers. Radiographic progression was
defined as an increase in SHS of >0.5 during a year.
During the trial, treatment adjustments were registered
in a separate ‘monitoring database’. Due to different for-
mats the ‘general’ and ‘monitoring databases’ cannot be
readily connected for analysis. Therefore, three samples of
100 patients who experienced a flare A, minor flare B and
major flare B, were randomly selected and, for these pa-
tients, data from both databases were manually combined
to explore the relationship between occurrences of flares
and previous and subsequent treatment adjustments.Statistical analysis
Descriptive statistics were used to determine the frequency
of flares.
All analyses were performed separately for the several
definitions of flare. Patients with flare A were compared
to patients without flare A; patients with major flare B
were compared to patients with minor flare B and pa-
tients with no flare B. Associations between flares and
functional ability, joint damage and VAS were tested
using mixed models, which is a robust method since it
takes into account all patients and can also handle missing
data not completely at random. HAQ was compared over
time between patients with and without a flare per visit,
with a linear mixed model (LMM). Flare, time and its
interaction term were entered as determinants. A Toeplitz
Fig. 1 Percentage of patients with a flare per performed visit over
time. Flare A: from any DAS to DAS >2.4 with an increase in DAS
of ≥0.6; minor flare B: from DAS ≤2.4 to DAS >2.4 with an increase
in DAS of <0.6; major flare B: from DAS ≤2.4 to DAS >2.4 with an
increase in DAS of ≥0.6. Note, flares are defined from year 2 to year 10
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data based on the log likelihood ratio test.
To evaluate long-term and dose–response effects of
the occurrence of a flare, patients were categorized ac-
cording to the number of flares experienced during
follow-up (none, 1, 2, or ≥3 flares for each definition
of flare). Mean HAQ during follow-up was compared
between the categories, as well as the HAQ at year 10
(based on a completers analysis). A Kruskal-Wallis test
was performed because of a non-Gaussian distribution
of the outcome variables. Cumulative probability plots
for mean HAQ during years 2 to 10 and radiographic
progression over 10 years were created to visualize the
differences between these categories.
For each VAS type, the difference between two subse-
quent scores was calculated. Percentages of patients with
an increase of ≥20 mm between two subsequent visits
were reported [17]. A generalized linear mixed model
(GLMM) was used to calculate the odds ratio for an in-
crease of ≥20 mm in VAS score (from the preceding
visit) during a flare. Flare and time were entered as de-
terminants. Separate GLMM were performed for an in-
crease of ≥20 mm (yes/no) in VASda, VASpain and
VASms as outcomes. Covariance matrices were chosen
based on their fit to the data, resulting in the Toeplitz
covariance matrix for VASda and the Identity covariance
matrix for VASpain and VASms.
SHS progression was evaluated yearly. In every patient,
for every year, the occurrence of a flare was checked. We
tested whether the occurrence of a flare was associated
with radiographic progression (defined as an increase in
SHS >0.5 during that year, yes/no). A GLMM with an
Identity covariance matrix was used. Flare, time and its
interaction term were again entered as determinants. To
compare SHS progression over 10 years in patients who
ever had a flare with those who never experienced a flare,
a Kruskal-Wallis test was used (based on a completers
analysis). Also, radiographic progression was compared
between the categories based on the numbers of flares per
patient (none, 1, 2, ≥3 flares).
Results
Frequency of flares
In 480 patients, sufficient follow-up data were available
to define presence or absence of a flare during at least
one visit. At baseline, patients had active disease with a
mean (standard deviation (SD)) DAS of 4.4 (0.9) and a
mean HAQ of 1.4 (0.7). During the first year of follow-
up, disease activity was increasingly suppressed. At the
first visit during year 2, patients had a mean DAS of 2.0
(1.0), a HAQ of 0.6 (0.6), and 320/480 patients (67 %)
had achieved a DAS ≤2.4.
During years 2 to 10, the majority of patients experi-
enced one or more flares. The prevalence of flares inaccomplished study visits decreased over time, for all
three definitions (Fig. 1). We found a prevalence of flare
A of 4–11 % per visit over time. Comparable frequencies
were found for major flare B (prevalence 4–9 %) and a
minor flare B occurred less often (prevalence 1–6 %). Flare
A occurred at least once in 321/480 patients (67 %). A
minor flare B occurred in 159/480 patients (33 %) and a
major flare B in 304/480 patients (63 %). In patients who
experienced at least one flare A, the median (interquartile
range (IQR)) number of flares during follow-up was 2
(1–4). For a minor flare B, this was 0 (0–1) and for
major flare B this was 2 (1–3).
When evaluating the percentage of patients who ever
achieved remission or low disease activity during total
follow-up, comparable percentages were found in patients
ever having a flare and patients never having a flare (re-
gardless of definition of flare, data not shown).
Table 1 shows the number of patients that experienced
none, 1, 2 and ≥3 flares during follow-up according to
all definitions. The circles in Fig. 2 represent the total of
visits in which presence or absence of flares was defined,
indicating the concordance and discordance between the
definitions.
Treatment
Exploration of three samples of 100 randomly selected
patients with flare A, minor flare B and major B demon-
strated that only approximately 25 % of flares were pre-
ceded by medication tapering. Although the study protocol
dictated to change medication or to increase the dose in
case of DAS >2.4, this was done only in ±60 % of flares. In
particular, in 11 % of cases of a minor flare B, rheumatolo-
gists scheduled an extra visit 1 month later, hoping to find
that the flare had resolved spontaneously. This indeed
Table 1 Dose–response effect of the number of flares on functional ability and radiographic progression




n (%) patients year 2 to year 10 at year 10
Total n = 480 median (IQR) median (IQR) median (IQR)
No. of flare A
0 159 (33) 0.2 (0.0–0.6) 0.0 (0.0–0.5) 1.3 (0.0–3.1)
1 100 (21) 0.5 (0.2–0.9) 0.4 (0.0–0.9) 2.3 (0.5–9.6)
2 73 (15) 0.6 (0.3–0.9) 0.6 (0.1–0.9) 3.0 (0.0–10.0)
≥3 148 (31) 0.8 (0.4–1.1) 0.8 (0.4–1.3) 4.3 (0.5–20.1)
p value <0.001 <0.001 0.005
No. of minor flare B
0 321 (67) 0.4 (0.1–0.8) 0.3 (0.0–0.9) 2.0 (0.0–6.9)
1 89 (19) 0.6 (0.4–1.0) 0.6 (0.3–1.0) 6.0 (0.5–26.0)
2 37 (8) 0.7 (0.3–1.1) 0.8 (0.3–1.1) 4.5 (0.1–26.8)
≥3 33 (7) 0.9 (0.6–1.1) 0.8 (0.4–1.3) 1.0 (0.0–13.5)
p value <0.001 <0.001 0.026
No. of major flare B
0 176 (37) 0.3 (0.0–0.8) 0.0 (0.0–0.8) 1.5 (0.0–3.5)
1 114 (24) 0.5 (0.2–0.9) 0.4 (0.0–0.9) 2.0 (0.5–10.3)
2 68 (14) 0.6 (0.3–0.9) 0.6 (0.1–0.9) 3.5 (0.5–17.0)
≥3 122 (25) 0.8 (0.4–1.1) 0.8 (0.3–1.1) 4.5 (0.3–17.3)
p value <0.001 <0.001 0.009
Due to drop out, not all patients had a HAQ at year 10 available, or a SHS progression score from baseline to year 10
‘Flare A’ defined as DAS >2.4, with an increase in DAS of at least 0.6 from a previous DAS of any value. ‘Minor flare B’ defined as DAS >2.4, from a previous
DAS ≤2.4 with an increase of DAS <0.6. ‘Major flare B’ defined as DAS >2.4 from a previous DAS ≤2.4 with an increase in DAS ≥0.6
IQR interquartile range, HAQ health assessment questionnaire, SHS Sharp/ van der Heijde score
Fig. 2 Total number of flares during year 2 to year 10 in all patients
(n = 480), according to the following definitions: Flare A (n = 882/
11,458): from any DAS to DAS >2.4 with an increase in DAS ≥0.6;
Minor flare B (n = 281/11,458): from DAS ≤2.4 to DAS >2.4 with an
increase in DAS <0.6; Major flare B (n = 721/11,458): from DAS ≤2.4
to DAS >2.4 with an increase in DAS ≥0.6. It indicates the concordance
and discordance between the definitions of flare. Note, more than one
flare according to the same definition or according to another
definition can occur in the same patient
Markusse et al. Arthritis Research & Therapy  (2015) 17:232 Page 4 of 9occurred in 73 % of those situations. At the next evaluation
following a flare, a DAS ≤2.4 was achieved again in 60 % of
patients. According to our definition of flare, the remaining
40 % of patients could have a flare A at this evaluation,
not a flare B (as this definition required a previous
DAS of ≤2.4).Functional ability
The mean (SD) HAQ in patients at a visit with a flare A
was 1.04 (0.63), and in patients at a visit with no flare A
0.53 (0.56). Patients with a minor flare B and a major
flare B had a mean HAQ of 0.85 (0.55) and 0.96 (0.60),
respectively, compared to 0.53 (0.57) for patients with
no flare B. Following the LMM, compared to the absence
of a flare, a flare A was associated with an increase in
HAQ of 0.251 (p < 0.001). Compared to the absence of a
flare, a minor flare B was associated with an increase in
HAQ of 0.059 (p = 0.001), while a major flare B was ac-
companied by an increase in HAQ of 0.226 (p < 0.001).
The difference in functional ability at the time of a minor
flare compared to a major flare was small (mean differ-
ence in HAQ 0.167; p < 0.001).
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higher the mean HAQ over time and the HAQ at year
10 (Table 1 and Fig. 3).
Visual analogue scales
Increases in each type of VAS were higher in patients
with a flare than in patients without a flare, regardless of
definition (Table 2). The odds ratios for an increase in
VAS ≥20 mm during a flare are reported in Table 2.
Joint damage progression
Over 10 years, SHS progression in completers was
lowest in patients without any flare during follow-up,Fig. 3 Cumulative probability plots of the mean functional ability (measure
year 10 of follow-up, stratified for definition and number of flares. a Accord
least 0.6 from a previous DAS of any value). b According to the definition o
of DAS <0.6). c According to the definition of major flare B (DAS >2.4 fromand increased with the number of flares A and major
flares B (Table 1 and Fig. 4). Proportions of patients
without any radiographic progression can be derived
from Fig. 4.
Over time, during a year where a flare A occurred,
the adjusted odds ratio (OR) of developing SHS pro-
gression was 1.74 (95 % confidence interval (CI) 1.07–
2.85; p = 0.027), compared to no flare A as reference
category. Patients with a minor flare B had an adjusted
OR of 2.11 (95 % CI 0.87–5.13; p = 0.101) to develop
SHS progression and patients with a major flare B had
an adjusted OR of 1.72 (95 % CI 1.01–2.91; p = 0.044),
both compared to the absence of a flare B.d with the health assessment questionnaire (HAQ)) during year 2 to
ing to the definition of flare A (DAS >2.4, with an increase in DAS of at
f minor flare B (DAS >2.4, from a previous DAS ≤2.4 with an increase
a previous DAS ≤2.4 with an increase in DAS ≥0.6)
Table 2 Changes in patient’s assessments of disease activity, pain and morning stiffness and odds ratios for an increase of at least
20 mm in visual analogue scales for these outcomes during the presence of a flare, compared to the absence of a flare (reference
category)
Change in VASda Change in VASpain Change in VASms
Median IQR Median IQR Median IQR
No flare A 0 −8 to 5 0 −8 to 5 0 −8 to 6
Flare A 17 3 to 40 17 3 to 35 11 0 to 29
No flare B 0 −8 to 5 0 −8 to 5 0 8 to 6
Minor flare B 7 −4 to 20 5 −4 to 18 5 −5 to 16
Major flare B 18 4 to 41 18 3 to 37 12 0 to 31
Increase in VASdaa Increase in VASpaina Increase in VASmsa
ORb 95 % CI ORb 95 % CI ORb 95 % CI
No flare A ref ref ref ref ref Ref
Flare A 8.47 7.30–9.83 8.35 7.20–9.69 5.63 4.84–6.55
No flare B ref ref ref ref ref Ref
Minor flare B 3.10 2.35–4.07 2.84 2.15–3.75 2.32 1.73–3.12
Major flare B 8.76 7.46–10.28 8.59 7.32–10.08 5.90 5.01–6.94
aIncrease ≥20 mm from the previous VAS
bAdjusted for time
CI confidence interval, IQR interquartile range, OR odds ratio, ref reference category, VASda visual analogue scale of disease activity, VASpain visual analogue scale
of pain, VASms visual analogue scale of morning stiffness
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In this post-hoc analysis of the BeSt study, we deter-
mined the short-term and long-term effects of flares de-
fined using the original DAS. During a flare, functional
ability decreased and patients reported higher VAS for
disease activity, pain and morning stiffness. In addition,
joint damage progression occurred more often when a
patient experienced a flare during that year. Long-term
assessments showed a higher loss of functional ability
and more radiographic progression in patients who had
suffered a flare, and there was a dose–response relation
with the number of flares over time.
The definition of a flare in RA is still in development
[1–3]. There may be transient periods of symptoms for
which patients do not contact their rheumatologist. It is,
however, determined that flares involve a deterioration
of patient-reported outcomes, such as functional ability
and VAS of general health, pain and morning stiffness
[4, 6]. It has also been suggested that DAS28 is a useful
instrument to define flares [5], and that registration of a
flare should be followed by treatment intensification [3–6].
However, treatment intensification for a flare that may
spontaneously resolve might constitute overtreatment.
Therefore we monitored short- and long-term disease
outcomes in relation to the occurrence of flares in the
BeSt study.
We formulated three definitions of a disease flare based
on the original DAS as obtained in the BeSt study. Over
10 years, besides the DAS measurements, functional abil-
ity was assessed 3-monthly using the HAQ, and patient’s
assessments of pain, disease activity and morning stiffnesson a VAS were registered. Comparable prevalence of flare
A and major flare B were found, as a result of overlapping
definitions (Fig. 2). Minor flare B occurred less often. This
might be explained by the rather strict definition, which
required an increase of DAS to above 2.4 but of less than
0.6 compared to the previous DAS. Still, there was a statis-
tically significant increase in HAQ in case of a minor flare
B, although this was not a clinically relevant increase, and
a trend was seen for increasing number of flares with de-
creasing functional ability (Table 1 and Fig. 3). In 11 % of
minor flare B, rheumatologists did not adjust medication.
In 73 % of these cases the next DAS was again ≤2.4. This
appears to illustrate that (minor) flares will spontaneously
remit and need no additional therapy. We have to stress,
however, that these are very small numbers and, if true,
then only for minor flares. Numerically, there appeared to
be slightly more joint damage progression in patients who
suffered a minor flare B compared to patients who never
experienced a minor flare B (Fig. 3), although a dose–
response relationship could not be demonstrated. The
dose–response relationships should be interpreted care-
fully anyhow, as individual patients may have various types
of flares in various frequencies.
The treatment protocol required stepwise tapering
and discontinuation of antirheumatic drugs if the
DAS was ≤2.4 during at least 6 months. We won-
dered if reducing medication could have triggered
flares. Only in 25 % of the flares, by whichever definition,
had medication been tapered at the preceding visit.
This could be linked to our finding of a higher flare preva-
lence during the early years of follow-up and decreasing
Fig. 4 Cumulative probability plots of radiographic progression (measured with the Sharp/ van der Heijde score (SHS)) during 10-year follow-up,
stratified for definition and number of flares. a According to the definition of flare A (DAS >2.4, with an increase in DAS of at least 0.6 from a
previous DAS of any value). b According to the definition of minor flare B (DAS >2.4, from a previous DAS ≤2.4 with an increase of DAS <0.6).
c According to the definition of major flare B (DAS >2.4 from a previous DAS ≤2.4 with an increase in DAS ≥0.6)
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ported that during year 1 and 2 of follow-up, when a low
DAS was achieved, and particularly if DAS was ≤2.4 twice
in a row, there was a high probability that the next DAS
would also be ≤2.4 [19]. During later years of follow-up, this
probability was even higher, up to 95 % (data not shown).
The decrease shown in Fig. 1 can be either an overesti-
mation or an underestimation, as patients with sustained
(drug-free) remission are more likely to drop out [20] and,
although patients were instructed to visit their rheumatolo-
gist at the moment of a flare, flares between two study visits
might have been missed. Despite this, we suggest that when
a treat-to-target strategy is adopted from the start andcontinued over time, RA may become relatively indolent in
most patients. Since a dose–response relationship between
the number of flares and the degree of long-term func-
tional disability and joint damage was demonstrated, one
could also hypothesize that targeted treatment should be
even stricter than required in the BeSt study. Rheumatolo-
gists need to be further encouraged to adjust medication
each time a flare is registered rather than hope for a spon-
taneous improvement. In addition, on the condition that
protocol violations would not occur even more often, the
treatment target may be set lower, for instance at remis-
sion [10]. The disease activity over time may then be lower
and episodes of high disease activity more rare. However,
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with higher turnover of medication in some patients, and
considerable costs. Setting the treatment target lower will
also influence the definition of flare.
A recent study examined the frequency of flares in a
cohort of patients with established RA [21]. Flares were
self-reported by the patients through 6-monthly ques-
tionnaires. During 3 years of follow-up, 99 % of the pa-
tients reported at least one flare, with a frequency of
54–74 % per evaluation. These percentages suggest a
higher flare frequency than in our study (67–69 % of our
patients had at least one flare during 9 years; frequency
4–11 % per visit). Possibly, the notion of a flare as expe-
rienced by patients only partially overlaps with our
DAS-based flare definitions. Also, the reported flares were
inventoried retrospectively, whereas we relied on DAS
increases as measured at the time of the study visits.
Since Bykerk et al. reported that patients with higher
disease activity tended to report more flares [21], the
fact that the majority of our patients had low disease
activity during most of the observation time may have
conditioned a reduced flare frequency [22].
We may have underestimated the prevalence of flares,
as we missed short-term subjective flares by focusing on
3-monthly DAS measurements for our flare definition.
This will, however, not affect the associations found be-
tween the presence of flares and functional ability loss,
increase in VAS scores, and joint damage progression.
Another limitation of our study could be the amount of
missing data. Patients have dropped out of the study (up
to 38 % at year 10) or may have missed some visits. To
avoid the influence of missing data, we performed mixed
models. This approach takes into account the correlation
of repeated measurements within a patient and between
variables when handling the missing data.Conclusion
In patients with RA a flare in disease activity is associ-
ated with functional disability, more pain and morning
stiffness, and more radiographic progression, both in the
short-term and the long-term. Therefore, it seems ap-
propriate to intensify therapy after each flare. Any risk
of overtreatment in case of a disease flare that would
spontaneously remit may be less serious than the risk
of undertreatment resulting in long-term disability and
joint damage. Continued targeted therapy might reduce
the frequency of flares, suggesting that with an adequate
treatment strategy RA may become more indolent. In that
case, it is possible that tight monitoring in patients who
achieved persistent low disease activity may be exchanged
for longer monitoring intervals, under the condition that
patients who suspect a flare can be readily assessed and
treatment can be adjusted if necessary.Abbreviations
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